Gland Pharma Limited

Gland Pharma Limited is a Hyderabad-based pharmaceutical company specializing in complex generic injectables. Established in 1978, the firm operates predominantly on a business-to-business (B2B) model, offering development, manufacturing, and marketing services for sterile injectables across diverse therapeutic areas. Its products encompass liquid vials, freeze-dried vials, pre-filled syringes, ampoules, and oncology formulations. The company maintains extensive manufacturing facilities across India, supported by dedicated research and development capabilities. Gland Pharma has built long-standing relationships with leading global pharmaceutical firms, supplying injectables to major regulated markets including the United States, Europe, Canada, and Australia, as well as maintaining a targeted presence in the Indian domestic market. Following its acquisition by Shanghai Fosun Pharmaceutical in 2017, Gland Pharma expanded its global commercial footprint. The organization emphasizes regulatory compliance and quality control across its production footprint to meet stringent international standards for sterile injectable manufacturing.

Gland Pharma raised Rs 1,943.86 crore from 70 anchor investors ahead of its IPO by allocating 1,29,59,089 equity shares at Rs 1,500 per share. Key participants included the Government of Singapore, Smallcap World Fund, Goldman Sachs, Nomura, alongside domestic institutional funds such as Axis Mutual Fund, SBI Mutual Fund, ICICI Prudential Mutual Fund, and Aditya Birla Sun Life Mutual Fund.